

AMENDMENTS

Amendments in the specification:

On page 8 of the specification, please delete, in their entirety, paragraphs [0023], including the phrase "BRIEF DESCRIPTION OF THE DRAWINGS", through [0025].

On page 9 of the specification, please delete, in their entirety, paragraphs [0026] and [0027].

On pages 28-29 of the specification, please amend paragraph [0092] as follows:

Raji B-lymphoma cells were obtained from the American Type Culture Collection (ATCC, Rockville, MD), and were grown in RPMI 1640 medium containing 12.5% fetal bovine serum (Hyclone, Logan, UT), supplemented with glutamine, pyruvate, penicillin and streptomycin (Life Technologies, Grand Island, NY). Briefly, 3.75×10^5 cells were incubated for 2 days with the indicated concentration of drug-mAb conjugate in 1.5 mL of tissue culture medium in wells of 24-well plates. The cells were then transferred to T25 flasks containing 20 ml of medium, and incubated for up to 21 days, or until the cells had multiplied 16-fold. Viable cell counts using Trypan blue were performed at day 0, day 2, and then every 3-5 days. From the growth rate of untreated cells, the doubling time was calculated, and the Fraction Surviving was calculated from the time required for treated cells to multiply 16-fold, assuming that the doubling time was not affected by treatment. A single remaining viable cell could be readily detected. At a concentration of drug-mAb conjugate of 1 μ g/mL the DOX-LL1 conjugate shows a three-orders of magnitude difference in the fraction of surviving cells, in comparison to the DOX-MN-14 conjugate. **See Figure 2.**

On page 29 of the specification, please amend paragraph [0093] as follows:

a) Treatment in a solid tumor xenograft model. Groups of athymic nude mice were injected subcutaneously with DU145 human prostate cancer cells. After approximately two weeks, when palpable prostate tumor xenografts had grown in the animals, half were treated with a single dose of the drug-antibody conjugate 2-PDOX-RS7, and half were left untreated (controls). ~~Figure 3, shows the growth of the tumor xenografts in untreated mice versus the growth of xenografts in mice treated with 2-PDOX-RS7. It shows a~~ A therapeutic effect was observed in ~~for~~ animals treated with the drug-antibody conjugate, in terms of delayed growth of the xenografts.

On page 29 of the specification, please amend paragraph [0094] as follows:

b) Treatment of systemic cancer in an animal model. NCr-SCID mice, in groups of ten animals, were each given an intravenous injection of a suspension of 2.5×10^6 cells of the human Burkitt's B-cell lymphoma cell line, Raji, by tail-vein injection. Five days later, animals were left untreated or treated with single doses of either 350 μ g DOX-LL1 or 150 μ g 2-PDOX-LL1. ~~Figure 4 shows the result of the experiment.~~ Untreated animals became paralyzed and died at around 23 days post-injection of the Raji cells, from systemic cancer. Animals treated with DOX- and 2-PDOX-conjugates of the LL1 antibody survived over an extended period corresponding to around a four-fold increase in life expectancy for the 2-PDOX-LL1-treated animals, and an even greater increased life expectancy for the DOX-LL1-treated animals.

On page 29 of the specification, please amend paragraph [0095] as follows:

c) Treatment of systemic cancer in an animal model. NCr-SCID mice, in groups of ten animals, were each given an intravenous injection of a suspension of 2.5×10^6 cells of the human Burkitt's B-cell lymphoma cell line, Raji, by tail-vein injection. Five days later, animals were left untreated or treated with single doses of either 150 μg 2-PDOX-LL1 or 150 μg of 2-PDOX-MN-14 (non-specific control antibody conjugate). **Figure 5 shows the result of the experiment.** Untreated animals became paralyzed and died at around 23 days post-injection of the Raji cells, from systemic cancer, as [[do]] did animals treated with the 2-PDOX-MN-14 conjugate. Animals treated with 2-PDOX-LL1 antibody conjugate survived over an extended period.